



Management Biographies

Klaus Schollmeier, PhD, Chief Executive Officer

Dr Schollmeier (born in 1957) joined Graffinity Pharmaceuticals AG as CEO in 2003 and became CEO of Santhera as Graffinity Pharmaceuticals and MyoContract combined businesses in 2004. Prior to joining the biotechnology industry in 2003, he served as Managing Director of the Healthcare/Biotechnology Group at ING-BHF Bank for ING Group Europe. Prior to that, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific responsibilities included Head of Oncology/Immunology research at BASF's central laboratories in Ludwigshafen, Germany, and Senior Director of Biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, USA (1989 to 1993). His business functions included General Manager of BASF Pharma Netherlands from 1996 to 1998 and Vice President and General Manager for Western Europe thereafter. From 1994 to 1995 he led BASF's acquisition and integration of Boots Pharmaceuticals. Dr Schollmeier holds a PhD in Biology from the University of Düsseldorf, Germany, and in 1991 he was appointed adjunct Research Associate Professor at the Boston University Medical School, Massachusetts, USA.

Barbara Heller, Chief Financial Officer

Ms Heller (born in 1967) joined Santhera as Chief Financial Officer in 2005. Prior to that Barbara Heller was with Bank Vontobel, an independent Swiss private banking and investment banking group, as a member of the senior management team. She joined Vontobel in 1997 and held several positions in investment banking and corporate finance. In 1991, she started her professional career in international corporate banking and capital markets at Bank Leu, today a member of the Credit Suisse Group, where she was promoted to Head of Corporate Finance/Financial Engineering. Ms Heller received a Masters degree from University of Zurich, Switzerland, in 1991 in Economics and Business Administration, with emphasis on Corporate Finance and Econometrics.

Thomas Meier, PhD, Chief Scientific Officer

Dr. Meier (born 1962) was founder and former Chief Executive Officer of MyoContract prior to the business combination with Graffinity Pharmaceuticals that leads to Santhera. In 1999, Dr Meier became an independent research group leader and lecturer at the Department of Pharmacology & Neurobiology at the Biozentrum of the University of Basel, Switzerland, where he established MyoContract. Dr Meier received his PhD from the University of Basel, Switzerland, in 1992 and subsequently joined the University of Colorado Health Sciences Center, USA. He has a distinguished scientific track record and is author of several papers in the field of neuromuscular research. Dr Meier won the International Research Fellowship Award from the NIH, USA, and has received a long-term fellowship from the Human Frontier Science Foundation.

Helmut Kessmann, PhD Chief Business Officer

Dr Kessmann (born 1960) joined Graffinity Pharmaceuticals in 2001 as Chief Business Officer and since the business combination of Graffinity Pharmaceuticals and MyoContract, continued in that role for Santhera. In 1996, Dr Kessmann co-founded Discovery Technologies, a biotechnology company in Basel, Switzerland, which was integrated into US-based Discovery Partners International in 1999 and had a successful IPO in 2000 (merged 2006 with Infinity Pharmaceuticals). Prior to that, and following a post-doc in the USA, he held various research management positions at Ciba-Geigy, now Novartis. Dr Kessmann studied biology, philosophy and business administration and completed his doctorate in biochemistry 1988 at the University of Münster, Germany. Dr Kessmann is a member of the Board of Directors of Oy Juvantia Pharma Ltd.